Maven Bio vs Idexx Laboratories

Side-by-side comparison of AI visibility scores, market position, and capabilities

Idexx Laboratories leads in AI visibility (94 vs 37)
Maven Bio logo

Maven Bio

EmergingHealthcare

General

Boston biopharma AI platform automating competitive landscape, regulatory intelligence, and clinical research for DayOne and ZS Associates; YC $3.1M Pags/Splash seed competing with Citeline and Evaluate for AI-powered pharma knowledge work.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1085 of 1158
AI Consensus
72%
Trend
up
Per Platform
ChatGPT
35
Perplexity
29
Gemini
28

About

Maven Bio is a Boston, Massachusetts-based AI platform for biopharma knowledge work — backed by Y Combinator with $3.1 million in seed funding led by Pags Group, Splash Capital, and NVO Group with YC participation, following a $500,000 pre-seed from YC in September 2023 — providing biopharma companies, consultancies, and investors with domain-specific AI modules built on curated biopharma industry data that automate the research, analysis, and synthesis tasks that pharmaceutical knowledge workers perform manually. Founded in 2023 by Michael Brady and Arjun Murthy and operating with an 8-person team in Boston, Maven Bio serves customers including DayOne and ZS Associates (the global biopharma consulting firm) with a platform that converts biopharma questions into decisions faster through AI-powered access to curated drug development, clinical, and regulatory knowledge.

Full profile
Idexx Laboratories logo

Idexx Laboratories

LeaderHealthcare Tech

Enterprise

Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.

AI VisibilityBeta
Overall Score
A94
Category Rank
#19 of 290
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
92
Gemini
88

About

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.

Full profile

AI Visibility Head-to-Head

37
Overall Score
94
#1085
Category Rank
#19
72
AI Consensus
71
up
Trend
stable
35
ChatGPT
99
29
Perplexity
92
28
Gemini
88
39
Claude
94
31
Grok
99

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.